The increase is close to inflation and wage growth but much steeper than the atypically small increase in 2022.
The average annual premium for employer-sponsored single and family coverage increased by 7% in 2023, an increase from 2022, but roughly in line with the rate of inflation (5.8%) and wage growth (5.2%), according to the annual KFF Employer Health Benefits Survey.
The survey, which was completed by 2,133 firms, showed that the average annual premium for single coverage was $8,435 and for family coverage, $23,968. Workers, on average, covered 17% of single coverage ($1,401 of $8,435) and 29% of family coverage ($6,575 of $23,968). The average worker contribution for family coverage was considerably higher ($8,334, or 38% of the premium vs. $5,889, or 25%) for workers employed by small firms (3-199 employees) than for those working for large ones (200 or more employee). There wasn’t much difference between small and large firms when it came single coverage, the survey found.
The 7% premium increase is larger than the 2% increase for single coverage in 2022 and the 1% increase in premiums for family coverage. However, 2022 was an outlier because the premiums that year reflected the decrease in utilization of healthcare services in the previous years due to the COVID-19 pandemic
First author Gary Claxton, senior vice president, the director of the Program on the Health Care Marketplace, and his colleagues, noted that increases in health insurance premiums have typically outpaced inflation and wage growth. During the past 10 years, for example, the average family premium has increased by 47% compared with a 30% increase in inflation and 42% increase in wages. But in the past five years, the 22% growth in the average family premium has been closer to the 21% growth in inflation and lower than the 27% increase in wage growth.
This is the 25th year that KFF, formerly known as the Kaiser Family Foundation, has conducted the survey. The response rate to the survey which was fielded from January to July of this year, was 15%, which is similar to the response rate the past two years.
Claxton and his colleagues reported the results of the survey in a Health Affairs article that was published this morning.
Here are some other findings from the survey:
FDA Updates for Week of May 13: First Bispecific Antibody for Solid Tumor
May 18th 2024The FDA has approved a new type of bispecific antibody to treat small cell lung cancer and an additional indication for Breyanzi for patients with follicular lymphoma. The agency has set review date for gene therapy for enzyme deficiency. In addition, Biogen have Eisai hve begun a rolling submission of subcutaneous Leqembi for Alzheimer’s disease.
Read More
Omega-3s For Dry Eye Disease? Not the Answer According to This Study
May 17th 2024Some research has suggested that omega-3 fatty acid supplements could help treat dry eye disease. But Korean investigators reported results from a randomized clinical trial this week in JAMA Ophthalmology tthat showed no benefit.
Read More
FDA Updates for Week of May 13: First Bispecific Antibody for Solid Tumor
May 18th 2024The FDA has approved a new type of bispecific antibody to treat small cell lung cancer and an additional indication for Breyanzi for patients with follicular lymphoma. The agency has set review date for gene therapy for enzyme deficiency. In addition, Biogen have Eisai hve begun a rolling submission of subcutaneous Leqembi for Alzheimer’s disease.
Read More
Omega-3s For Dry Eye Disease? Not the Answer According to This Study
May 17th 2024Some research has suggested that omega-3 fatty acid supplements could help treat dry eye disease. But Korean investigators reported results from a randomized clinical trial this week in JAMA Ophthalmology tthat showed no benefit.
Read More
2 Commerce Drive
Cranbury, NJ 08512